A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary) ; Entrectinib (Primary) ; Erlotinib (Primary) ; Ipatasertib (Primary) ; Olaparib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Vemurafenib (Primary) ; Vismodegib (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel
- Indications Cancer
- Focus Therapeutic Use
- Acronyms CUPISCO
- Sponsors Roche
- 23 Jan 2019 Planned End Date changed from 16 Apr 2022 to 25 Jun 2022.
- 23 Jan 2019 Planned primary completion date changed from 16 Apr 2022 to 25 Jun 2021.
- 18 Apr 2018 New trial record